Cochrane · systematic review · CD014383
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Bighelli, I, Rodolico, A, Siafis, S, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 4 · 57.1%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table ‐ Continuation compared to reduction of polypharmacy for people with schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life: clinically important change ‐ not reported Summary of findings table ‐ Continuation vs reduction of polypharmacy | no estimate extracted | NR | No studies |
Service use – readmission to hospital – total Summary of findings table ‐ Continuation vs reduction of polypharmacy | RR 0.75 [0.25, 2.24] | 1 study · 127 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total Summary of findings table ‐ Continuation vs reduction of polypharmacy | RR 4.37 [0.77, 24.88] | 3 studies · 176 participants | Very low Downgraded: risk of bias, imprecision |
Functioning – mean endpoint score GAF (high = good) – total Summary of findings table ‐ Continuation vs reduction of polypharmacy | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Global state: relapse/exacerbations of psychosis ‐ not reported Summary of findings table ‐ Continuation vs reduction of polypharmacy | no estimate extracted | NR | No studies |
Leaving the study early due to any reason – overall acceptability (totals of time points combined) Summary of findings table ‐ Continuation vs reduction of polypharmacy | RR 0.44 [0.29, 0.68] | 5 studies · 319 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: ≥ 1 adverse effect – total Summary of findings table ‐ Continuation vs reduction of polypharmacy | RR 5 [0.28, 88.53] | 1 study · 14 participants | Very low Downgraded: imprecision, inconsistency |